INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, on Tuesday announced that its director of neuroscience, CJ Barnum, Ph.D., will be giving a scientific talk and presenting a poster on Alzheimer’s drug candidate XPro1595 at the TNF Conference on June 4, 2019. According to the update, “A Phase 1b biomarker-directed study to target soluble tumor necrosis factor in Alzheimer’s (“AD”) patients,” is the title of the poster and talk in which Barnum will discuss INmune Bio’s clinical approach to treating Alzheimer’s disease. “XPro1595 has been represented at the TNF Conference for more than a decade. I am often told that the support and feedback provided by TNF experts at this conference has gone a long way in shaping the enormous dataset that we enjoy with XPro1595,” Barnum stated in the news release. “I am very excited to share how these efforts have paid off and that we are days away from enrolling the first patient in our Alzheimer’s disease trial.”
To view the full press release, visit http://nnw.fm/m51wG
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.INmuneBio.com
NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com